Licoisoflavone B

Name: Licoisoflavone B
Brand: MedChemExpress
SKU: HY-N3388
Rating: 4.5 (0 reviews)

Cat. No.: HY-N3388 Purity: 99.46%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Licoisoflavone B is an orally active flavonoid found in licorice. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Licoisoflavone B inhiibits superoxide anion generation and superoxide anion-induced lipid peroxidation. Licoisoflavone B binds tightly to Lassa virus nucleoprotein and can be used as a nucleoprotein antagonist of Lassa virus. Licoisoflavone B exhibits anti-mutagenic activity
against carcinogenic mutagen, by preventing DNA damage. Licoisoflavone B can be used for the research of psoriasis, Lassa fever, inflammation and cancer.

For research use only. We do not sell to patients.

Licoisoflavone B Chemical Structure

CAS No. : 66056-30-2

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Licoisoflavone B binds directly to purified SCD1 protein with a K_d of 7.1 μM^[1].
Licoisoflavone B (0-15 μM; 24 h) exhibits no cytotoxicity toward HaCaT keratinocytes at concentrations ≤12 μM^[1].
Licoisoflavone B (9 μM; 24 h) attenuates IL-17-induced SCD1 upregulation and lipid droplet accumulation in HaCaT keratinocytes^[1].
Licoisoflavone B (9 μM; 24 h) suppresses IL-17-driven hyperproliferation of HaCaT keratinocytes^[1].
Licoisoflavone B (100 μM; 10 min) inhibits superoxide anion-induced lipid peroxidation in a cell-free lecithin-based assay with an IC₅₀ of 2.7 μM, and exhibits a 92.5% inhibitory ratio at 100 μM^[2].
Licoisoflavone B (100 μM; 20 min) inhibits superoxide anion generation in a cell-free xanthine-xanthine oxidase assay with an IC₅₀ of 31.2 μM and exhibits a 58.3% inhibitory ratio at 100 μM^[2].
Licoisoflavone B binds tightly to Lassa virus nucleoprotein (PDB ID: 3MX5) with a binding affinity of -10.1 kcal/mol^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HaCaT keratinocytes
Concentration:	0, 1, 3, 6, 9, 12, 15 μM
Incubation Time:	24 h
Result:	Showed no detectable cytotoxicity at concentrations ≤9 μM after 24 h of treatment. Maintained cell viability near baseline levels at concentrations ≤9 μM. Caused a significant reduction in cell viability at 15 μM.

In Vivo

Licoisoflavone B (40-160 mg/kg; p.o.; daily; 6 days) alleviates Imiquimod (HY-B0180)-induced psoriasis-like pathology in male C57BL/6 mice^[1].
Licoisoflavone B (40-160 mg/kg; p.o.; daily; 6 days) is well-tolerated in healthy male C57BL/6 mice at doses up to 160 mg/kg administered orally daily for 6 days, with no detected hepatic or renal toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (male, 6-8 weeks old, Imiquimod-induced psoriasis-like model)^[1]
Dosage:	40 mg/kg; 80 mg/kg; 160 mg/kg
Administration:	p.o.; daily; 6 days
Result:	Reduced Psoriasis Area and Severity Index (PASI) cumulative scores, erythema scores, thickness scores, and scaling scores compared to untreated imiquimod-exposed mice. Decreased epidermal thickness and splenic weight index in Imiquimod-induced mice. Reduced splenic Th17 cell proportions. Markedly decreased skin tissue mRNA expression of IL-17 and RORγt. Significantly reduced protein expression of keratinocyte hyperproliferation markers KRT17, Ki67, and SCD1 in skin lesions.

Molecular Weight

352.34

Formula

C₂₀H₁₆O₆

CAS No.

66056-30-2

Appearance

Solid

Color

White to yellow

SMILES

OC1=C(C=CC(C)(C)O2)C2=CC=C1C3=COC4=CC(O)=CC(O)=C4C3=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (141.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8382 mL	14.1908 mL	28.3817 mL
5 mM	0.5676 mL	2.8382 mL	5.6763 mL
10 mM	0.2838 mL	1.4191 mL	2.8382 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (3.55 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.46%

Select Batch:

Data Sheet (278 KB) SDS (394 KB)

COA (248 KB) HNMR (131 KB) LCMS (105 KB)

Handling Instructions (2659 KB)

References

[1]. Liu Y, et al. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Front Pharmacol. 2026;17:1754729. Published 2026 Feb 16. [Content Brief]

[2]. Toda S, et al. Inhibitory effects of isoflavones in Sophora mooracrotiana on lipid peroxidation by superoxide[J]. Pharmaceutical biology, 2002, 40(6): 422-424.

[3]. Faisal Ahmed S, et al. Licoisoflavone B and glabridin from Glycyrrhiza glabra as potent nucleoprotein antagonists of Lassa virus: insights from molecular docking, dynamics simulation, PCA, and DFT studies. J Genet Eng Biotechnol. 2025;23(3):100544. [Content Brief]

[4]. Vijayalakshmi U, et al. Yeast extract-mediated elicitation of anti-cancerous compounds licoisoflavone B, licochalcone A, and liquirtigenin in callus cultures of Glycyrrhiza glabra[J]. BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology, 2019, 100(4).

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8382 mL	14.1908 mL	28.3817 mL	70.9542 mL
	5 mM	0.5676 mL	2.8382 mL	5.6763 mL	14.1908 mL
	10 mM	0.2838 mL	1.4191 mL	2.8382 mL	7.0954 mL
	15 mM	0.1892 mL	0.9461 mL	1.8921 mL	4.7303 mL
	20 mM	0.1419 mL	0.7095 mL	1.4191 mL	3.5477 mL
	25 mM	0.1135 mL	0.5676 mL	1.1353 mL	2.8382 mL
	30 mM	0.0946 mL	0.4730 mL	0.9461 mL	2.3651 mL
	40 mM	0.0710 mL	0.3548 mL	0.7095 mL	1.7739 mL
	50 mM	0.0568 mL	0.2838 mL	0.5676 mL	1.4191 mL
	60 mM	0.0473 mL	0.2365 mL	0.4730 mL	1.1826 mL
	80 mM	0.0355 mL	0.1774 mL	0.3548 mL	0.8869 mL
	100 mM	0.0284 mL	0.1419 mL	0.2838 mL	0.7095 mL